L-NMMA acetate是一氧化氮合酶抑制剂, 对其所有亚型均有抑制作用，包括NOS1，NOS2和NOS3。与nNOS (大鼠), eNOS (人), 和 iNOS (小鼠)结合 的Ki值分别为0.18，0.4，6 μM。

L-NMMA acetate is an inhibitor of nitric oxide synthase of all NOS isoforms (i.e. NOS1, NOS2, and NOS3). The Ki values are 0.18, 0.4, and 6 μM for nNOS, eNOS, and iNOS, respectively.

L-NMMA inhibits vasodilator responses to the endothelium-dependent vasodilator ACh but not to the endothelium-independent NP. L-NMMA does not affect isoprenaline-induced relaxation[2]. The inhibitory effect of L-NMMA is unchanged by previous incubation with D-arginine while it is prevented by L-arginine (L-Arg). L-NMMA, starting from 100 μM, produces a concentration-dependent inhibition of the evoked relaxations (2Hz); maximal inhibition at 1 mM averaged about 35%. The Superfusion of L-NMMA decreases arteriolar diameter and causes dose-dependent increases in arteriolar tone. The onset of action of L-NMMA is nearly immediate. NE induced dose-related vasoconstriction that is significantly potentiated by L-NMMA[3].

53308-83-1

C9H20N4O4

248.28

Methylarginine acetate;Tilarginine acetate

H2O:50 mg/mL (201.39 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years